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Abstract
Background: Since it was initiated in 2002, the China Free Antiretroviral Treatment (ART) Program has been progressing
from an emergency response to a standardized treatment and care system. As of December 31, 2009, a total of 81,880
patients in 31 provinces, autonomous regions, and special municipalities received free ART. Gender differences, however, in
mortality and immunological response to ART in this cohort have never been described.
Objective: To understand whether women and men who enrolled in the China National Free ART Program responded
equally well to the treatment.
Methods: A retrospective analysis of the national free ART databases from June 2006–December 2008 was performed. HIV-
infected subjects who were 18 years or older, ART naı ¨ve at baseline, and on a 3TC regimen enrolled in the program from
June 1 to December 31, 2006, were included in this study, then followed up to 2 years.
Results: Among 3457 enrolled subjects who met the inclusion criteria, 59.2% were male and 40.8% female. The majority of
the subjects were 19–44 years old (77%) and married (72%). Over the full 24 months of follow-up, the mortality rate was
19.0% in males and 11.4% in females (p=0.0014). Males on therapy for 3–24 months were more likely to die than females
(HR=1.46, 95% CI: 1.04–2.06, p=0.0307) after adjusting for baseline characteristics. Compared to men, women had higher
CD4+ counts over time after initiating ART (p,0.0001).
Conclusions: Our study showed that women had an overall lower mortality and higher CD4+ counts than men in response
to ART treatment, which may be attributed to adherence, biological factors, social, cultural and economic reasons. Further
study is needed to explore these factors that might contribute to the gender differences in mortality and immunological
response to ART.
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Introduction
In the past two decades, advances in antiretroviral treatment
(ART) have resulted in dramatic declines in death rates in
countries where treatment is available, transforming a once-fatal
disease into a manageable chronic illness [1–2]. Despite this
remarkable achievement, there remain major questions about
whether treatment outcomes differ for women and men and what
factors may drive such variation. Although a number of studies
have examined gender differences in HIV disease progression and
in the response to ART, using survival, HIV-1 RNA levels, and
lymphocyte subset levels to assess response to treatment, the
findings have differed with regard to the association of gender with
these measures. Early studies showed a more rapid clinical
progression in women, which was attributed to the delay in
starting ART and to other gender-related conditions such as
discrimination, violence, and stigma [3]. More recently, natural
history cohorts observed that early in infection, women have
significantly lower amounts of the virus in their blood than do men
but suffer the loss of immune cells and develop AIDS just as swiftly
as men [4–6]. A cohort study of 2196 HIV infected treatment-
naı ¨ve adults conducted in South Africa reported that gender was
not significantly associated with survival after adjusting for baseline
clinical and immunovirological status [7]. Conversely, several
studies have found evidence that gender was associated with
response to ART [8–11]. Given that HIV/AIDS has affected
more women worldwide than any other life threatening infectious
disease [12] and that half of the estimated 30.8 million HIV-
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better understanding of the gender influence in survival and
immunological responses to ART. As more and more women are
impacted by the HIV epidemic in China [14], it has also become
of utmost importance to understand whether women and men
respond differently to ART treatment.
In response to the growing HIV epidemic in China, the Chinese
government responded in 2002 with a national ART program
called the National Free Antiretroviral Therapy Program
(NFATP), which provides antiretroviral (ART) drugs free to those
most in need [15]. To monitor and evaluate the success of the
NFATP, China also established a Free ART Database in 2004 to
















Mean (std. dev.) 38.42 (10.17) 38.75 (10.15) 37.94 (10.17)
Median (IQR) 37 (31–44) 37 (31–44) 37 (31–43) 0.0544
19–44 2671 (77.35) 1574 (77.01) 1097 (77.86) 0.1007
45–59 642 (18.59) 375 (18.35) 267 (18.95)
$60 140 (4.05) 95 (4.65) 45 (3.19)
Marital Status
Single 486 (14.06) 397 (19.39) 89 (6.31) ,.0001
Married 2475 (71.59) 1385 (67.66) 1090 (77.30)
Divorced 214 (6.19) 146 (7.13) 68 (4.82)
Widowed 279 (8.07) 116 (5.67) 163 (11.56)
Unknown 3 (0.09) 3 (0.15) 0 (0.00)
Transmission Routes
FPD 1167 (33.76) 586 (28.63) 581 (41.21) ,.0001
IDU 720 (20.83) 620 (30.29) 100 (7.09)
STI 1299 (37.58) 676 (33.02) 623 (44.18)
Other/Unknown 271 (7.84) 165 (8.06) 106 (7.52)
Any Past and/or Current Signs/Symptoms at
Enrollment
Yes 2993 (86.58) 1820 (88.91) 1173 (83.19) ,.0001
No 464 (13.42) 227 (11.09) 237 (16.81)
Baseline AZT Regimen
Yes 734 (21.23) 434 (21.20) 300 (21.28) 0.9578
No 2723 (78.77) 1613 (78.80) 1110 (78.72)
CD4+ Counts (cells/uL)
Mean (std. dev.) 125.00 (106.36) 117.08 (104.84) 136.73 (107.54)
Median (IQR) 109 (36–190) 96 (31–180) 131 (47–200) ,.0001
$200 674 (21.66) 359 (19.32) 315 (25.12) ,.0001
50–199 1496 (48.07) 877 (47.20) 619 (49.36)
,50 942 (30.27) 622 (33.48) 320 (25.52)
Hemoglobin
Normal or Grade 0 2580 (80.65) 1607 (84.94) 973 (74.45) ,.0001
Grade 1 or 2 504 (15.75) 235 (12.42) 269 (20.58)
$Grade 3 115 (3.59) 50 (2.64) 65 (4.97)
Liver Function (AST/ALT)
$100 U/L 179 (5.74) 140 (7.52) 39 (3.10) ,.0001
,100 U/L 2942 (94.26) 1721 (92.48) 1221 (96.90)
1The group frequencies may not sum to total due to missing values.
2P-values are from Chi-square test for categorical variables and non-parametric test for continuous variables.
doi:10.1371/journal.pone.0022707.t001
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all patients participating in the NFATP [16]. As of December
2009, the Free ART Database had data from 81,880 patients in 31
provinces and autonomous regions who had received ART
through the NFATP [17]. A recent analysis of factors associated
with treatment outcome in patients registered in this database
suggested a positive association of female gender with good
treatment outcome [18], but factors that might explain this
association were not explored further. In this study, we extend the
previous analysis to examine other factors that might explain the
gender-related difference in treatment outcome, using a subset of
the NFATP cohort that were treatment naı ¨ve when entering the
program, received initial treatment with a HAART regimen
containing 3TC (Lamivudine), and had at least two-year potential
follow-up time since initiating therapy.
Methods
This analysis was approved by the institutional review board
(IRB) of the National Center for AIDS/STD Control and
Prevention (NCAIDS), China CDC. Per the IRB review,
individual informed consent was waived because this analysis
used currently existing data collected during the course of routine
treatment and care and data were reported in aggregate without
use of individual identifying information.
Study Design and Population
As described previously [17,18], the NFATP enrolled HIV-
infected subjects who met the national ART treatment guidelines,
which includes CD4+ T-cell count ,200 cells/uL (,350 cells/uL in
the revised edition in 2008) or World Health Organization (WHO)
stage III or IV disease. After enrollment, subjects were followed at
week 2, months 1, 2, 3, and then every 3 months thereafter. Clinical
information - including clinical signs and symptoms, self-reported
adherence, and laboratory test results – were collected at the time of
treatment initiation and at each subsequent follow-up visit. WHO
staging and TB data were not collected. The local health providers
collectedthesedata onsite,usingstandardcase reportformsand then
transferred these data to the national database.
A retrospective analysis was performed on subjects enrolled in
the NFATP who had data in the Free ART Database from June
2006–December 2008. Eligible subjects had to be enrolled in the
NFATP between June 1–December 31, 2006 to allow for two
years of follow-up, at least 18 years of age, ART-naı ¨ve at time of
enrollment, and received a HAART regimen that included 3TC
(Lamivudine) as their initial therapy including D4T +3TC+NVP;
D4T +3TC +EFV; AZT+3TC +NVP; or AZT+3TC +EFV. A
3TC regimen was required because it became readily available in
China in 2005, has lower toxicity than other regimens, and has
become the norm for initial therapy in China.
After enrollment, subjects were followed up to 2 years to observe
ART response including immunological function (CD4+ counts),
side effects to the ART, adherence and mortality. Data from
enrollment to visits through December 31, 2008 were included in
the analysis to allow the last-enrolled subjects to have up to 2 years
of follow-up after treatment initiation. For those who were
enrolled earlier, follow-up visits after 24 months were eliminated
from this analysis. Subjects with missing gender, missing treatment
initiation date, first-line regimen with less than three single drugs
or including a combination of AZT+D4T (not allowed due to drug
interaction) were excluded from this study. A total of 4791 subjects
enrolled into the NFATP from June 1 to December 31, 2006. Of
those, 3457 subjects were eligible for this study. When subjects
were lost to follow-up or terminated treatment during the two-year
follow-up, they were censored from the study, and the length on
study was defined as the date of enrollment to the date of the last
available visit. Subjects who transferred from one site to another
within the program were considered as adherent to study visits.
Study Measures
Demographic and baseline characteristics were obtained,
including gender, age, marital status, mode of HIV transmission,
Figure 1. Subjects Attrition over Time. Ineligible subjects: 1. ART initiation regimens were not D4T+3TC+NVP, D4T+3TC+EFV, AZT+3TC+NVP,
AZT+3TC+EFV: n=806; 2. ART termination or death date were prior to ART initiation date (data entry error): n=10; 3. Not ART naı ¨ve at enrollment:
n=423; 4. Age ,18 years old or missing at ART initiation: n=82; 5. Gender missing: n=13.
doi:10.1371/journal.pone.0022707.g001
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population, the HIV transmissions were mainly through commercial
blood donations, noted as the former plasma donor (FPD);
intravenous drug use (IDU); and sexually transmitted infection
(STI). Laboratory test data included absolute CD4+ cell counts,
hemoglobin and liver function, which were collected at baseline and
follow-upvisits.CD4+T-cellcountswerecollectedduringatleastone
of the follow-up visits (months 3, 6, 12, 18 and 24). When the CD4+
count was not available for a scheduled follow-up visit, an alternative
CD4+ count within 61.5 months of the scheduled visit time window
was used for the analysis. HIV viral load was not available for analysis
as a treatment outcome, since the lack of local resources during this
time period prevented testing for viral load in most subjects. Based on
Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events (GSAPAE) for HIV positive subjects only,
hemoglobin was categorized as three groups (normal or grade 0:
.100 g/dL; grade 1 or 2: 75–100 g/dL; and grade 3+: ,75 g/dL),
and liver function tests including AST and ALT were categorized as
$100 U/L vs. ,100 U/L (2.56ULN). Self-reported current signs
and symptoms of HIV infection such as fever, diarrhea, rash, fatigue,
weight loss and lymphadenopathy, were collected at baseline. Self-
reported medication adherence and fourteen self-reported adverse
events (including appetite change, vomiting, sleeping difficulties,
abdominal pain, dry skin, skin rush, numb limbs, pain limbs, fatigue,
body shape change, hair loss, vision change, headache, and vivid
dreams) were also collected at follow-up visits. The self-reported
medication adherence was collected as an ordinal variable with 0, 1–
5, 6–10, 11–15,16–20 and .20timesmissingdosesamonth,butwas
redefined as a binary measure (100% vs. ,100%) for this study.
W h e nas u b j e c td i dn o tr e p o r th a v i n ga n ym i s s i n gd o s e ,t h i ss u b j e c t
was considered as perfectly adherent to ART medication (100%);
otherwise, the subject was considered as less than 100% adherent (a
subject reported missing at least one dose during follow-up).
Statistical Analyses
Chi-square was used to examine the differences in proportion of
deathsbetweenmalesandfemales.Kaplan-Meiersurvivalcurvesand
Log-Rank test were used to display and test gender differences in
mortality over 2 years after initiating ART treatment. Univariate and
multivariable Cox proportional hazard models were constructed to
examine the gender effect on mortality. The demographic and
baseline characteristics as well as medication adherence were
included as the potential risk factors. The proportional hazard (PH)
assumption over time was tested using a graphic approach and time-
dependent variables where appropriate. When the PH assumption
was not met because of a time/gender interaction, PH models were
constructed separately for the subset of subjects who were in the
program for up to three months (0–3 months) and for the larger
subset who were in the program for up to 24 months (3–24 months).
Another subset analysis was conducted among those who had CD4+
counts at baseline and at least three test results available after
enrollment. The mixed linear model (MIXED) with repeated
measurements was used to examine the effect of gender and other
potential covariates on CD4+ count change over time. The
unstructured covariance was assumed for the covariance structure
on CD4+ counts. Model fit statistics (e.g. AIC, BIC, etc) were used to
choose the best covariance structure.
Results
Demographic and Baseline Characteristics
Among 3457 enrolled subjects who met the inclusion criteria,
59.2% were male and 40.8% females (Table 1). Majority of the
subjects were 19–44 years old (77% for both genders), married
(68% for males and 77% for females). Among all transmission
routes, sexual transmission was the most frequent for both males
and females (33% for males and 44% for females), followed by
IDU for males (30%) and FPD for females (41%). Over two-thirds
of all subjects had experienced signs/symptoms of HIV infection,
but men had significantly more occurrences (89% vs. 83%,
p,0.001). The median baseline CD4+ counts were lower for men
compared with women (96 vs. 131 cells/uL, p,.0001) and more
men than women had CD4+ counts ,50 cells/uL at enrollment
(33.5% vs. 25.5%, p,.0001). More females had a grade 1 or
higher abnormal hemoglobin (26%) but more males had abnormal
liver function ($100 U/L) at baseline (8%). Among 3457 patients,
136 (3.9%) were lost to follow-up and 99 (2.9%) terminated ART
(Figure 1). No subjects transferred out of the program. The median
follow-up time for both male and female subjects was 21.3 months.
Two-Year Mortality
Overall, 443 (12.8%) of 3457 subjects were died in the first two
years after initiating ART treatment. Among them, 151 (10.7%) of
1410 females and 292 (14.3%) of 2047 males were died. A
significantly greater death incidence from Kaplan-Meier (KM)
estimates in males 24 months after enrollment was detected when
compared with female subjects (19.0% vs. 11.4%, p=0.0014). The
estimated two-year overall survival rate, unadjusted for covariates,
was 84.3%; two-year survival rate for females was significantly
higher than for males (Figure 2, 88.6% vs. 81.0%, p=0.0014).
We observed that mortality was higher during the early phase of
the treatment (0–3 months). Of the 443 deaths observed in the first
two years, about 248 (56%) occurred in the first three months after
ART initiation. In addition, for multivariate analysis adjusting for
covariates, the PH assumption of constant hazard was not satisfied
over the entire 24-month period. There was a time/gender
interaction (p=0.0411), with the hazard rate for females changing
over time. Therefore, the separated analyses were further
performed: those in the program for 0–3 months and those in
the program for greater than 3 months. The PH assumption was
satisfied for these two separate groups. There was no difference in
survival between males and females among those early deaths
(Figure 3, Panel A). In contrast, for the other 195 (44%) subjects
who died after three months, the survival rate for females was
significantly higher than for males (Figure 3, Panel B). The results
from the multivariable Cox models showed that there was no
evidence of gender effect on early mortality (p=0.0940) but males
were at greater risk of dying after being on treatment for at least
three months (HR=1.46, 95% CI: 1.04–2.06, p=0.0307) after
adjusting for HIV transmission routes, baseline and current signs
and symptoms, and baseline CD4+ counts (Table 2). Although
gender was not associated with the mortality during the early stage
of treatment (0–3 months), there was a strong association with
mortality for two other covariates (having baseline signs/
symptoms and lower CD4+ counts) in this early period even
stronger than later in treatment (3–24 months).
CD4+ T-Cell Count Response to ART Treatment
CD4+ T-cell count was examined to assess gender differences in
immunological response to ART. Due to limited resources, CD4+
counts were only done at a few visits for some subjects. Thus, we
were unable to adjust for CD4+ cell count change over time in the
multivariate proportional hazard models described earlier. We
were, however, able to make inferences on CD4+ change over
time for subjects who had baseline and at least 3 follow-up CD4+
count test results. The results from the multivariable mixed model
with repeated measurements indicated that the average CD4+ cell
count change over time in males was significantly lower than in
Gender Difference in Outcomes of ART in China
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being older, infected through FPD, having past and current signs
and symptoms, lower baseline CD4+ counts, without abnormal
liver function, and less than 100% ART adherence (Table 3).
Self-Reported Adverse Events
We attempted to examine the self-reported adverse events at the
selected follow-up visits (months 3, 6, 12, 18, and 24). When the
events were missing at a specific month, the imputation was made
by using an available data point within 61.5 months around that
specific follow-up visit. The results indicated that females tended to
report more adverse events at most follow-up visits. For example,
the overall proportion of self-reporting at least one adverse event
among females was significantly higher than males at 3 months
(28.7% vs. 23.5%, p=0.0019), 6 months (23.5% vs. 19.0%,
p=0.0053), and 12 months (18.6% vs. 14.7%, p=0.0095).
Discussion
Our current study on this homogenously-treated population
confirmed that females have better survival at 2 years on ART
than men do. Compared to men, females had overall better
Figure 3. Early and After 3-Months Survival after on ART Treatment by Gender.
doi:10.1371/journal.pone.0022707.g003
Figure 2. Two-Years Survival on ART Treatment by Gender among 3457 Subjects.
doi:10.1371/journal.pone.0022707.g002
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consistent with others. Hall et al [8], using data from the CDC
national HIV/AIDS reporting system from 1996 to 2001,
observed that the risk for progression from HIV to AIDS or
death was greater for nonwhites, men, and older persons
compared with whites, women, and younger persons, respectively.
Collazos et al [9] found that women had better clinical and viro-
immunological responses than men and concluded that gender
played a small but significant role in outcome. An observational
study conducted in the US reported that lower pre-therapy CD4+
cell count, younger age, and female sex were all factors associated
with increased CD4+ cell count gains from month 3 to year 4 of
ART [3]. A recent study performed in Uganda and Zimbabwe on
the virologic and immunological outcomes of 300 HIV-infected
Table 2. Relationship of HIV/AIDS Mortality with Demographic and HIV/AIDS Related Characteristics.
Overall (N=3457)
On Treatment for ,3 Months
(N=456)
On Treatment for 3–24 Months
(N=3001)
Unadjusted Unadjusted Adjusted Unadjusted Adjusted
Died/n (%) HR (95% CI)
1,2 HR (95% CI)
1 HR (95% CI)
1,3 HR (95% CI)
1 HR (95% CI)
1,3
Gender
Male 292/2047 (14.26) 1.38 (1.13–1.68) 1.12 (0.86–1.45) 1.31 (0.95–1.81) 1.56 (1.15–2.11) 1.46 (1.04–2.06)
Female 151/1410 (10.71) 1.00 1.00 1.00 1.00 1.00
Age (years)
19–44 330/2671 (12.35) 1.00 1.00 1.00
45–59 86/642 (13.40) 1.05 (0.83–1.33) 1.34 (0.95–1.88) NS 1.26 (0.90–1.77) NS
$60 27/140 (19.29) 1.64 (1.11–2.43) 1.22 (0.74–2.01) 1.47 (0.77–2.79) NS
Marital Status
Single 55/486 (11.32) 1.00 1.00 1.00
Married 309/2475 (12.48) 1.03 (0.78–1.38) 1.16 (0.79–1.71) NS 0.97 (0.64–1.49) NS
Divorced 44/214 (20.56) 1.87 (1.26–2.78) 1.02 (0.61–1.71) NS 1.54 (0.82–2.88) NS
Widowed 35/279 (12.54) 1.05 (0.69–1.61) 1.44 (0.80–2.60) NS 1.08 (0.58–2.00) NS
Transmission Routes
FPD 169/1167 (14.48) 1.00 1.00 1.00 1.00 1.00
IDU 96/720 (13.33) 1.00 (0.78–1.28) 0.40 (0.27–0.58) 0.54 (0.35–0.84) 1.28 (0.90–1.80) 1.27 (0.87–1.85)
STI 144/1299 (11.09) 0.78 (0.62–0.97) 0.76 (0.57–1.02) 0.78 (0.54–1.12) 0.57 (0.40–0.82) 0.57 (0.39–0.84)
Other/Unknown 34/271 (12.55) 0.91 (0.63–1.31) 0.93 (0.58–1.46) 0.91 (0.54–1.54) 0.63 (0.33–1.18) 0.55 (0.27–1.12)
Any Past and/or Current
Signs/Symptoms at Enrollment
Yes 428/2993 (14.30) 4.79 (2.86–8.01) 5.66 (1.81–17.66) 5.71 (1.39–23.39) 2.66 (1.49–4.78) 1.91 (1.02–3.57)
No 15/464 (3.23) 1.00 1.00 1.00 1.00 1.00
CD4+ Counts
$200 26/674 (3.86) 1.00 1.00 1.00 1.00 1.00
50–199 145/1496 (9.69) 2.51 (1.66–3.82) 3.50 (1.60–7.66) 3.48 (1.58–7.67) 1.98 (1.20–3.25) 1.95 (1.18–3.21)
,50 188/942 (19.96) 5.70 (3.78–8.59) 5.66 (2.63–12.18) 4.60 (2.11–10.06) 3.14 (1.90–5.21) 3.04 (1.82–5.07)
Hemoglobin
Normal or Grade 0 263/2580 (10.19) 1.00 1.00 1.00
Grade 1 or 2 100/504 (19.84) 2.13 (1.69–2.69) 1.35 (1.00–1.82) NS 1.59 (1.10–2.29) NS
$Grade 3 32/115 (27.83) 3.25 (2.25–4.69) 2.14 (1.37–3.35) NS 1.91 (0.97–3.76) NS
Liver Function: AST/ALT
$100 U/L 37/179 (20.67) 1.95 (1.39–2.74) 1.35 (0.86–2.10) NS 1.83 (1.08–3.11) NS
,100 U/L 341/2942 (11.59) 1.00 1.00 1.00
Self-reported ART Adherence
100% 267/2444 (10.92) 1.18 (0.92–1.52) 1.14 (0.75–1.72) NS 0.91 (0.66–1.25) NS
,100% 78/819 (9.52) 1.00 1.00 1.00
1HR: hazard ratio; NS: the covariate was either statistically insignificant (not entered into the initial full multivariable Cox model) or deleted during the model selection
procedure; the proportional hazard assumption was tested using graphic approach (univariate model only) and time-dependent variable (both univariate and
multivariable models).
2The PH-assumption for the univariate model (gender) among all subjects was satisfied (p=0.3000) but was violated for the overall multivariate final model (p=0.0411).
3The PH-assumption was satisfied for 0–3 months (p=0.6228) and 3–24 months (p=0.4097) final multivariate models. The R-square for the final multivariable models
are 86% for 0–3 months and 12% for 3–24 months.
doi:10.1371/journal.pone.0022707.t002
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(NRTIs), women showed a 2.3 fold higher rate of virologic
suppression compared with men after 48 weeks on ART [11].
Our finding that mortality did not differ by gender in the first 3
months on treatment may suggest that a certain proportion of
patients entered therapy at a late enough stage of disease
progression that there is little opportunity for therapy to work.
This hypothesis is supported by our findings that mortality was
much higher in the first 3 months and that it was strongly
associated with greater baseline signs/symptoms and lower
baseline CD4+ counts. After 3 months the hazard rate of females
diverged from that of males.
There are a number of possible explanations for our findings: (1)
biologically better response to the drugs; (2) better adherence to
treatment; and (3) other factors such as co-morbid conditions,
general health status, and psychosocial differences. Our analysis,
together with the recent findings of Rotger, et al. [19], Heath,
et al. [20], and Van, et al. [21], suggest that there may be a real
difference between females and males in biological response to the
ARTs. Because the NFATP data are from a registry, we had
limited items that measured co-morbidity, general health status,
and psychosocial factors. While a higher proportion of males had
abnormal liver function, suggesting possible co-infection with
hepatitis B or C, this did not explain the treatment response
difference. Males were also much more likely to have been infected
through injection drug use, suggesting both poorer overall health
status and poorer psychosocial status. Our results suggest that
there may be very different factors influencing early and later
Table 3. Impact of Gender and Other Factors on Immunology Responses to ART Treatment Over Time among 996 Subjects.
Unadjusted Adjusted
Est. Coef. (Std. Err.)
{ p-value Est. Coef. (Std. Err.)
{ p-value
Gender
Male 233.34 ( 4.79) ,.0001 222.11 ( 4.79) ,.0001
Female 0.00 0.00
Age (years)
$60 242.72 (12.53) 0.0007 230.70 (12.81) 0.0166
45–59 225.22 ( 5.93) ,.0001 215.07 ( 5.77) 0.0091
19–44 0.00 0.00
Marital Status
Widowed 20.81 (10.75) 0.9397 NS
Divorced/Separated 7.46 (11.68) 0.5230 NS
Married/Live Together 213.75 ( 6.90) 0.0465 NS
Single 0.00
Transmission route
Other 15.83 ( 8.75) 0.0704 33.43 ( 8.50) ,.0001
STI 20.71 ( 5.59) 0.0002 30.26 ( 5.63) ,.0001
IDU 46.35 ( 7.51) ,.0001 42.40 ( 7.74) ,.0001
FPD 0.00 0.00
Any Past and/or Current Signs/Symptoms
Yes 259.89 ( 6.19) ,.0001 214.36 ( 6.06) 0.0179
No 0.00 0.00
Baseline CD4+ Counts (cell/uL)
,50 2212.6 ( 6.44) ,.0001 2205.1 ( 7.04) ,.0001
50–199 2111.8 ( 5.81) ,.0001 2104.4 ( 6.14) ,.0001
$200 0.00 0.00
Hemoglobin
Grade 3 & Grade 4 261.59 (14.63) ,.0001 NS
Grade 1 & Grade 2 261.44 ( 6.67) ,.0001 NS
Normal & Grade 0 0.00
Liver Function (AST/ALT)
Yes 27.74 (12.24) 0.0235 24.95 (11.08) 0.0244
No 0.00 0.00
Self-Reported ART Adherence
100% 11.87 ( 5.51) 0.0313 11.46 ( 5.20) 0.0277
,100% 0.00 0.00
{Est. Coef.: estimated coefficient; Std. Err.: standard error.
doi:10.1371/journal.pone.0022707.t003
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since it might reveal genetic or other biological markers that would
improve the personalization of treatment regimens for both
women and men.
Our study has limitations because of the nature of the
information that was retrospectively obtained from the Free
ART database from 31 provinces of China, certain levels of recall
bias and measurement variations may be introduced in data
collection. Second, HAART initiation relies on both WHO
staging and CD4+ count; however, WHO stage data was not
collected until 2010. Although signs/symptom data were analyzed,
this may not truly reflect WHO stage. Third, we were not able to
analyze viral load response because it was infrequently collected in
the field. Fourth, the CD4+ analysis was restricted to the subjects
who had CD4 tests 3 times or more after the treatment initiation.
Although the demographic characteristics (e.g. gender, age, and
marital status) from this subset were comparable to the rest of the
population, this subset may not truly represent the entire
population of subjects who were included in the analysis. Fifth,
self-reported treatment adherence data may not be completely
accurate, and it is possible that some treatment response
differences might still be attributable to difference in adherence.
Finally, we had limited information collected on other possible
explanatory factors, such as co-morbidities, general health, and
psychosocial status.
Our findings of lower mortality rates among females after 3
months on ART and better immunological response among
females in a subset of our cohort demonstrate a difference in
outcomes between men and women in the first 2 years of
treatment with ART. Given the limitation of data it is unclear
whether this is due to environmental, psychological, or biological
factors. Further controlled prospective data collection should be
undertaken to determine whether biological factors related to
gender play an important role in determining outcomes to
treatment. Further prospective studies within our own treatment
cohort are necessary to explore other possible explanatory factors
such as adherence, co-morbidities, general health status and
psychosocial factors.
Recommendations: Viral load is a gold standard to evaluate
whether patients are virologically suppressed after ART. It is
important to collect viral load data at certain time points after
ART. Intensive adherence counseling for patients on failing
regimens would increase the optimization of first line regimens and
save money in the long term.
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